Forma Therapeutics to Participate in Upcoming Investor Conferences
Forma Therapeutics Holdings (Nasdaq: FMTX) announced participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Forma Therapeutics Holdings, Inc. (Nasdaq: FMTX), a clinical-stage biopharmaceutical company focused on rare hematologic diseases and cancers, today announced that company management will participate in two upcoming investor conferences:
- The Oppenheimer Rare & Orphan Disease Summit taking place Friday, May 21, 2021. Forma’s pre-recorded presentation will be available on May 21 at 8:00 a.m. EDT.
- The Jefferies Virtual Healthcare Conference taking place June 1-4, 2021. Forma will present on June 2 at 11 a.m. EDT.
Webcasts/audio recordings of the conference presentations will be available in the “News & Investors” section of Forma’s website at www.formatherapeutics.com.
About Forma Therapeutics
Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Our R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Our work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit. For more information, please visit www.FormaTherapeutics.com or follow us on Twitter @FORMAInc and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210517005098/en/